Reviva Pharmaceuticals Holdings, Inc. – NASDAQ:RVPH

Add to watchlist

$0.529

-1.27

-70.6%

Market closed

Open in about 6 hours

+45.16%

month

+45.16%

quarter

-64.98%

year

Market Cap	58.45M
Enterprise value	N/A

P/E	-3.58
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	N/A
Price/Book	7.14
PEG ratio	0.04
EPS	-1.71

Revenue	N/A
EBITDA	-36.49M
Income	-37.65M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH): Profit margin
Dec 2022	0	-8.11M
Mar 2023	0	-6.60M
Jun 2023	0	-12.44M
Sep 2023	0	-10.49M

Reviva Pharmaceuticals Holdings Financials Estimate

Q Y

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH): Analyst Estimates
Jun 2023	0	-12.44M
Sep 2023	0	-10.49M
Sep 2025	0	-5.84M
Dec 2025	0	-5.60M

Analysts Price target
Financials & Ratios estimates

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH): Debt to assets
Dec 2022	18923675	6.60M	34.92%
Mar 2023	12901523	7.11M	55.16%
Jun 2023	11842022	10.22M	86.31%
Sep 2023	5387041	13.90M	258.15%

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH): Cash Flow
Sep 2022	-4.00M	7.77M
Dec 2022	-4.69M	18.56K
Mar 2023	-7.95M	687.09K
Jun 2023	-5.31M	5.21M

Reviva Pharmaceuticals Holdings alternative data

Reviva Pharmaceuticals Holdings
Employees

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH): Employee count
Aug 2023	10
Sep 2023	10
Oct 2023	10
Nov 2023	10
Dec 2023	10
Jan 2024	10
Feb 2024	10
Mar 2024	10
Apr 2024	10
May 2024	15
Jun 2024	15
Jul 2024	15

Reviva Pharmaceuticals Holdings
Hedge Funds Holdings Q1 2023

0.94% -7.87%

of RVPH is owned by hedge funds

8 -15

hedge funds hold RVPH stock

139.09K -1.16M

shares is hold by hedge funds

RVPH hedge funds holdings changes

Reviva Pharmaceuticals Holdings
Insider Trading

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH): Insider trades (number of shares)
Period	Buy	Sel
Jun 2022	50000	0
Sep 2022	50000	0
Nov 2022	3000	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	18 Nov 2022	PATEL PURAV director director	Common Stock, par value $0.0001 per share	3,000	$4.69	$14,070
Purchase	30 Sep 2022	NARAYAN PRABHU officer: Chief Financial Officer officer: Chief Financial Officer	Common Stock, par value $0.0001 per share	50,000	$1.66	$83,000
Purchase	30 Jun 2022	NARAYAN PRABHU officer: Chief Financial Officer officer: Chief Financial Officer	Common Stock, par value $0.0001 per share	50,000	$1.21	$60,650
Purchase	1 Jun 2021	VEDANTA PARTNERS, LLC	Common Stock	1,330,000	$3.94	$5,237,540
Sale	8 Dec 2020	GLAZER CAPITAL, LLC	Ordinary Shares, no par value	367,000	$10.88	$3,992,960
Sale	7 Dec 2020	HUDSON BAY CAPITAL MANAGEMENT LP	Ordinary Shares, no par value	50,000	N/A	N/A
Sale	2 Dec 2020	GLAZER CAPITAL, LLC	Ordinary Shares, no par value	261	$11	$2,871
Sale	1 Dec 2020	GLAZER CAPITAL, LLC	Ordinary Shares, no par value	5,362	$11	$58,982
Sale	27 Nov 2020	GLAZER CAPITAL, LLC	Ordinary Shares, no par value	5,969	$10.9	$65,062
Sale	24 Nov 2020	GLAZER CAPITAL, LLC	Ordinary Shares, no par value	7,103	$10.9	$77,423

RVPH insider trading transactions

Reviva Pharmaceuticals Holdings
Executives

Insider	Age	Since	Compensation
Dr. Laxminarayan Bhat Ph.D. (1965) Founder, Chief Executive Officer, Pres & Director	60		$247,950

Reviva Pharmaceuticals Holdings
Latest News

Monday, 16 December 2024
17:18	Reviva Announces Proposed Public Offering	globenewswire.com
Wednesday, 11 December 2024
15:37	Reviva Pharmaceuticals: Upcoming Events May Generate Excitement, But Cash Is Low	seekingalpha.com
Thursday, 14 November 2024
17:25	Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights	globenewswire.com
Wednesday, 6 November 2024
08:00	Reviva to Present Positive Speech Latency Data for Brilaroxazine in Schizophrenia From the Phase 3 RECOVER Trial at the CNS Summit 2024	globenewswire.com
Thursday, 31 October 2024
08:00	Reviva to Participate in the UBS Global Healthcare Conference	globenewswire.com
Tuesday, 8 October 2024
08:00	Reviva to Participate in the 2024 Maxim Healthcare Virtual Summit	globenewswire.com
Wednesday, 2 October 2024
08:30	Reviva to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference	globenewswire.com
Wednesday, 21 August 2024
06:00	Reviva Pharmaceuticals Announces Pricing of $5.0 Million Underwritten Offering Priced At-the-Market Under Nasdaq Rules	globenewswire.com
Tuesday, 9 July 2024
08:00	Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Hypertension	globenewswire.com
Saturday, 1 June 2024
12:00	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH	accesswire.com
Thursday, 30 May 2024
19:20	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH	prnewswire.com
Wednesday, 29 May 2024
16:45	Reviva Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	globenewswire.com
Tuesday, 28 May 2024
08:00	Reviva Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	globenewswire.com
Thursday, 23 May 2024
12:41	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH	prnewswire.com
Tuesday, 21 May 2024
08:00	Reviva to Participate in the BIO International Convention	globenewswire.com
Thursday, 16 May 2024
20:55	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH	prnewswire.com
Wednesday, 15 May 2024
08:00	Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia	globenewswire.com
Tuesday, 14 May 2024
08:00	Reviva Reports First Quarter 2024 Financial Results and Recent Business Highlights	globenewswire.com
Monday, 13 May 2024
08:00	Reviva to Present New Preclinical Efficacy Data on Brilaroxazine in Idiopathic Pulmonary Fibrosis at 2024 ATS International Conference	GlobeNewsWire
Thursday, 28 March 2024
08:00	Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual Meeting	GlobeNewsWire
Tuesday, 26 March 2024
08:00	Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual Meeting	GlobeNewsWire
Monday, 11 March 2024
08:00	Reviva to Present at the UBS Virtual CNS Day	GlobeNewsWire
Tuesday, 20 February 2024
08:00	Reviva Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference	GlobeNewsWire
Tuesday, 23 January 2024
07:32	Brain Disease Cures: 3 Neuroscience Stocks Targeting Revolutionary Breakthroughs	InvestorPlace
Wednesday, 10 January 2024
08:00	Reviva to Present at Webull LIVE! Healthcare Webinar on January 17	Accesswire
Thursday, 30 November 2023
16:05	Reviva Pharmaceuticals to Participate in The Benchmark Company's Upcoming Discovery One-on-One Investor Conference	GlobeNewsWire
Thursday, 2 November 2023
03:11	Reviva Pharmaceuticals: Positive Results In Phase 3 But The Stock Is Back Where It Started	Seeking Alpha
Monday, 30 October 2023
07:41	Reviva Pharma's schizophrenia drug succeeds in late-stage study	Reuters
Wednesday, 27 September 2023
02:48	Reviva Pharmaceuticals: A Binary Event Approaches With Results From RECOVER	Seeking Alpha
Thursday, 7 September 2023
06:00	Reviva to Participate in the H.C. Wainwright 25th Annual Global Investment Conference	GlobeNewsWire

Frequently Asked Questions (FAQ)

What's the price of Reviva Pharmaceuticals Holdings stock today?

One share of Reviva Pharmaceuticals Holdings stock can currently be purchased for approximately $0.53.
When is Reviva Pharmaceuticals Holdings's next earnings date?

Unfortunately, Reviva Pharmaceuticals Holdings's (RVPH) next earnings date is currently unknown.
Does Reviva Pharmaceuticals Holdings pay dividends?

No, Reviva Pharmaceuticals Holdings does not pay dividends.
How much money does Reviva Pharmaceuticals Holdings make?

Reviva Pharmaceuticals Holdings has a market capitalization of 58.45M.
What is Reviva Pharmaceuticals Holdings's stock symbol?

Reviva Pharmaceuticals Holdings, Inc. is traded on the NASDAQ under the ticker symbol "RVPH".
What is Reviva Pharmaceuticals Holdings's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Reviva Pharmaceuticals Holdings?

Shares of Reviva Pharmaceuticals Holdings can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Reviva Pharmaceuticals Holdings's key executives?
Reviva Pharmaceuticals Holdings's management team includes the following people:
- Dr. Laxminarayan Bhat Ph.D. Founder, Chief Executive Officer, Pres & Director(age: 60, pay: $247,950)
Is Reviva Pharmaceuticals Holdings founder-led company?

Yes, Reviva Pharmaceuticals Holdings is a company led by its founder Dr. Laxminarayan Bhat Ph.D..
How many employees does Reviva Pharmaceuticals Holdings have?

As Jul 2024, Reviva Pharmaceuticals Holdings employs 15 workers, which is 50% more then previous quarter.
When Reviva Pharmaceuticals Holdings went public?

Reviva Pharmaceuticals Holdings, Inc. is publicly traded company for more then 6 years since IPO on 18 Oct 2018.
What is Reviva Pharmaceuticals Holdings's official website?

The official website for Reviva Pharmaceuticals Holdings is revivapharma.com.
Where are Reviva Pharmaceuticals Holdings's headquarters?

Reviva Pharmaceuticals Holdings is headquartered at 19925 Stevens Creek Boulevard, Cupertino, CA.
How can i contact Reviva Pharmaceuticals Holdings?

Reviva Pharmaceuticals Holdings's mailing address is 19925 Stevens Creek Boulevard, Cupertino, CA and company can be reached via phone at +40 85018881.

Reviva Pharmaceuticals Holdings, Inc.

revivapharma.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is headquartered in Cupertino, California.

+40 85018881

19925 Stevens Creek Boulevard
Cupertino, CA 95014

CIK: 0001742927
ISIN: US76152G1004
CUSIP: 76152G100